Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis

Yi-Wei Dong; Yan-Qiang Shi; Li-Wen He; Xi-Yu Cui; Pei-Zhu Su

doi:10.18632/oncotarget.18233

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis

Yi-Wei Dong, Yan-Qiang Shi, Li-Wen He, Xi-Yu Cui _ and Pei-Zhu Su

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:55478-55488. https://doi.org/10.18632/oncotarget.18233

Metrics: PDF 2053 views | HTML 2261 views | ?

Abstract

Yi-Wei Dong1,*, Yan-Qiang Shi1,*, Li-Wen He1, Xi-Yu Cui2 and Pei-Zhu Su2

1The Second Clinical Medical School of Southern Medical University, Guangzhou 510282, Guangdong, China

2Department of Gastroenterology, The First People’s Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan 528000, Guangdong, China

*These authors have contributed equally to this work and should be considered as co-first authors

Correspondence to:

Xi-Yu Cui, email: [email protected]

Pei-Zhu Su, email: [email protected]

Keywords: pancreatic neoplasms, metformin, prognosis, meta-analysis

Received: January 23, 2017 Accepted: April 29, 2017 Published: May 26, 2017

ABSTRACT

Background and aim: Recent epidemiological studies indicated that metformin might improve the survival of various cancers. However, its benefit on pancreatic cancer was controversial.

Methods: We performed this meta-analysis to investigate the benefit of metformin on pancreatic cancer. A comprehensive literature search was performed through PubMed, Cochrane Library and Embase. Relative risk (RR) and hazard ratio (HR) with 95% confidence interval (CI) were pooled.

Results: The meta-analysis of 2 randomized controlled trials including181 pancreatic patients, revealed that metformin use was not associated with an improved overall survival at 6 months (RR=0.90, 95% CI=0.67-1.21), overall survival (HR=1.19, 95% CI=0.86-1.63) and progression-free survival (HR=1.39, 95% CI=0.97-1.99). But the meta-analysis of 8 cohorts, involving 2805 pancreatic patients with diabetes, demonstrated a favorable result with improved overall survival (HR=0.78, 95% CI=0.66-0.92).

Conclusions: Observations in the cohort studies supported a favorable role of metformin while the data from randomized controlled trials did not support that. Therefore, more high-quality RCTs are warranted.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18233

Publication Alerts

Meta-Analysis:

Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis

Abstract